Altshuler Shaham’s Myriad Genetics MYGN Stock Holding History

Altshuler Shaham’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,341	Closed	-$41K	–	691
2021 Q1	$41K	Buy	+1,341	New	+$38.1K	﹤0.01%	317

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Altshuler Shaham's MYGN Position: Q2 2021 in Review

Altshuler Shaham sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 1,341 shares — an estimated $41K sold.

Altshuler Shaham first reported a position in MYGN in Q1 2021 and held it in 1 quarter. The position peaked at $41K in Q1 2021. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

Altshuler Shaham reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
Altshuler Shaham sold 1,341 Myriad Genetics shares in Q2 2021, an estimated $41K.
Altshuler Shaham first reported a position in Myriad Genetics in Q1 2021 and held it in 1 quarter.
Altshuler Shaham's Myriad Genetics position peaked at $41K in Q1 2021.
201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Altshuler Shaham's 13F filing for Q2 2021, filed 16 Aug 2021.